戴维医疗(300314) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 141,652,800, representing a 0.62% increase compared to CNY 140,779,300 in the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 31,018,510, a decrease of 22.84% from CNY 40,081,220 in the previous year[5]. - The net profit after deducting non-recurring gains and losses for Q3 2023 was CNY 23,543,540, down 35.43% from CNY 36,345,810 in the same period last year[5]. - Operating revenue for Q3 2023 reached ¥458.96 million, an increase of 31.21% compared to ¥349.79 million in the previous period[11]. - Net profit for Q3 2023 was ¥122.80 million, reflecting a growth of 61.70% from ¥75.94 million in the same period last year[11]. - Total operating revenue for the current period reached ¥458,961,630.27, a significant increase from ¥349,787,104.41 in the previous period, representing a growth of approximately 31.2%[22]. - Net profit for the current period was ¥122,795,311.05, compared to ¥75,939,978.19 in the previous period, reflecting a growth of approximately 62.0%[23]. Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 178.20% to CNY 69,934,680 compared to CNY 25,138,360 in the previous year[5]. - Cash flow from operating activities increased by 178.20%, amounting to ¥69.93 million, up from ¥25.14 million in the previous period[11]. - Cash flow from operating activities generated a net amount of ¥69,934,687.29, compared to ¥25,138,368.32 in the previous period, showing an increase of approximately 177.8%[24]. - The net cash flow from financing activities was -45,092,548.04 CNY in Q3 2023, compared to -30,531,004.92 CNY in Q3 2022, indicating a decrease of 47.8% year-over-year[25]. - The total cash and cash equivalents at the end of Q3 2023 amounted to 488,634,719.40 CNY, up from 431,386,919.15 CNY at the end of Q3 2022, representing an increase of 13.3%[25]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,313,767,009.25, reflecting a 4.69% increase from CNY 1,252,694,543.64 at the beginning of the year[5]. - As of September 30, 2023, the total assets of Ningbo David Medical Instruments Co., Ltd. amounted to CNY 1,313,767,009.25, an increase from CNY 1,254,874,318.44 at the beginning of the year, reflecting a growth of approximately 4.65%[18]. - Total current liabilities decreased to CNY 157,505,195.28 from CNY 176,629,990.11, a reduction of about 10.77%[20]. - The company reported a decrease in total liabilities to CNY 175,110,197.78 from CNY 195,812,818.02, a decline of about 10.15%[20]. - The total liabilities increased from 193,390,231.36 CNY to 195,812,818.02 CNY, with an adjustment of 2,422,586.66 CNY[26]. Shareholder Information - The company’s total number of ordinary shareholders at the end of the reporting period was 15,754[13]. - Major shareholders include Chen Zaihong with 24.69% and Chen Yunqin with 21.12% of the shares[13]. Other Financial Metrics - Investment income turned positive at ¥10.83 million, a significant improvement from a loss of ¥10.55 million in the previous period[11]. - Other income increased by 64.10% to ¥13.98 million, mainly due to an increase in government subsidies[11]. - The company experienced a 37.58% increase in operating costs, which totaled ¥192.65 million, driven by higher sales revenue[11]. - The company's construction in progress rose by 234.31% to ¥27.29 million, primarily due to increased expenditures on the new factory[11]. - The retained earnings increased to CNY 596,905,682.13 from CNY 517,310,371.08, showing a growth of approximately 15.36%[20]. - The company has maintained a stable capital reserve of CNY 175,534,430.38 throughout the reporting period[20]. Adjustments and Audits - The company has not undergone an audit for the Q3 2023 report, as stated in the documentation[31]. - The adjustments made in the financial statements reflect the implementation of new accounting standards starting in 2023[26].